Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United Laboratories ...

Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...

Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...